academic article

• Functional disability and other health-related quality-of-life domains: points to consider for clinical trials in systemic sclerosis..  Rheumatology (Oxford, England).  56:v17-v22. 2017
• Functional disability and other health-related quality-of-life domains: points to consider for clinical trials in systemic sclerosis.  Rheumatology.  2017
• Feasibility and Construct Validity of PROMIS and "Legacy" Instruments in an Academic Scleroderma Clinic.  Value in Health.  2012
• Feasibility and construct validity of PROMIS and "legacy" instruments in an academic scleroderma clinic..  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.  15:128-34. 2011
• Minimally important differences of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument..  The Journal of rheumatology.  38:1920-4. 2011
• Prevalence and correlates of sleep disturbance in systemic sclerosis--results from the UCLA scleroderma quality of life study..  Rheumatology (Oxford, England).  50:1280-7. 2011
• Association of gastrointestinal involvement and depressive symptoms in patients with systemic sclerosis.  Rheumatology.  2011
• Impact of Acute Gout Flares on Health Related Quality of Life (HRQOL) and Productivity in Patients with Chronic Gout.  Arthritis & Rheumatism-arthritis Care & Research.  2011
• Minimally Important Differences of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument.  The Journal of Rheumatology.  2011
• Prevalence and correlates of sleep disturbance in systemic sclerosis-results from the UCLA scleroderma quality of life study.  Rheumatology.  2011
• Association of gastrointestinal involvement and depressive symptoms in patients with systemic sclerosis..  Rheumatology (Oxford, England).  50:330-4. 2010
• Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument..  Arthritis and rheumatism.  61:1257-63. 2009
• Reliability and Validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument.  Arthritis & Rheumatism-arthritis Care & Research.  2009
• Development of a preliminary scleroderma gastrointestinal tract 1.0 quality of life instrument..  Arthritis and rheumatism.  57:1280-6. 2007
• Reliability, validity, and minimally important differences of the SF-6D in systemic sclerosis..  Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation.  16:1083-92. 2007
• Development of a preliminary scleroderma gastrointestinal tract 1.0 quality of life instrument.  Arthritis & Rheumatism-arthritis Care & Research.  2007
• Reliability, validity, and minimally important differences of the SF-6D in systemic sclerosis.  Quality of Life Research.  2007
• Assessment of SF-6D, a preference measure, in systemic sclerosis.  Arthritis & Rheumatism-arthritis Care & Research.  2006
• Development of the scleroderma gastrointestinal tract 1.0 (SSc-GIT1.0) quality of life instrument - Preliminary report.  Arthritis & Rheumatism-arthritis Care & Research.  2006
• Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study.  Annals of the Rheumatic Diseases.  2006
• Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial..  The Journal of rheumatology.  32:832-40. 2005
• Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial.  The Journal of Rheumatology.  2005
• Responsiveness of the health related quality of life (HRQL)instruments (SF-36 and HAQ-DI) in a systemic sclerosis (SSc) clinical trial.  Arthritis & Rheumatism-arthritis Care & Research.  2003